Analysts at StockNews.com began coverage on shares of Aware (NASDAQ:AWRE – Get Free Report) in a report released on Tuesday. The firm set a “buy” rating on the software maker’s stock.
Aware Price Performance
NASDAQ AWRE traded down $0.03 during mid-day trading on Tuesday, reaching $1.75. 169,799 shares of the stock were exchanged, compared to its average volume of 51,912. The stock has a market cap of $36.90 million, a P/E ratio of -5.30 and a beta of 0.81. Aware has a one year low of $1.05 and a one year high of $2.97. The stock has a 50 day simple moving average of $2.16 and a 200-day simple moving average of $1.96.
Aware (NASDAQ:AWRE – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The software maker reported ($0.05) earnings per share for the quarter. Aware had a negative return on equity of 9.01% and a negative net margin of 26.49%. The business had revenue of $4.32 million during the quarter.
Institutional Trading of Aware
Aware Company Profile
Aware, Inc, an authentication company, provides biometrics software products and solutions for government agencies and commercial entities in the United States, the United Kingdom, and internationally. The company offers biometric software solution, including Knomi, a mobile biometric framework which provides multiple biometric modality options; AwareABIS, an automated biometric identification system used for large-scale biometric identification and deduplication; AFIX suite used for small-scale law enforcement focused biometric identification; and AFIX Tracker for fingerprint, palmprint, and latent print identification, as well as AFIX Face, AFIX Verifier, AFIX Identifier, AFIX Comparator, AFIX Engine, and AFIX NIST Transaction Engine.
Featured Stories
- Five stocks we like better than Aware
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Where Do I Find 52-Week Highs and Lows?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Aware Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aware and related companies with MarketBeat.com's FREE daily email newsletter.